Assembly Biosciences is advancing a new class of oral therapeutics for the treatment of hepatitis B (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome.
Copyright West LLC. Minimum 15 minutes delayed.
- Assembly Biosciences Announces Move to Virtual-Only Annual Meeting of Stockholders on June 11, 2020
- Assembly Biosciences Reports Updates on Corporate Progress and First Quarter 2020 Financial Results
- Preclinical Data from Assembly Biosciences’ Microbiome Program in Ulcerative Colitis Featured in DDW 2020 Virtual Meeting Portal and Upcoming Journal Supplements
Jun 3, 2020 at 1:30 PM EDT
May 7, 2020 at 1:30 PM PDT
May 4, 2020 at 9:30 AM CDT